Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

New molecule shows promise in controlling HIV without using daily antiretroviral drugs

Scientists have created a new molecule that shows promise for controlling HIV without daily antiretroviral drugs. The molecule foils a wider range of HIV strains in the laboratory than any known broadly neutralizing HIV antibody and is more powerful than some of the most potent of these antibodies.

19 Feb 2015

UCSD researchers make new attempt to develop malaria vaccine candidate

Researchers at University of California, San Diego School of Medicine used algae as a mini-factory to produce a malaria parasite protein. The algae-produced protein, paired with an immune-boosting cocktail suitable for use in humans, generated antibodies in mice that nearly eliminated mosquito infection by the malaria parasite.

19 Feb 2015

San Francisco AIDS Foundation unveils new mobile testing unit

On Valentine's Day, San Francisco AIDS Foundation unveiled a new mobile testing unit, an essential element in the plan to eliminate HIV transmission in San Francisco. The new unit—a 33-foot-long vehicle outfitted specifically for HIV and STI testing—will increase the availability of free testing in neighborhoods across the city at times when other HIV testing sites are closed.

19 Feb 2015

Bacteria's DNA can pass trait to offspring in a way similar to parents' own DNA

It's a firmly established fact straight from Biology 101: Traits such as eye color and height are passed from one generation to the next through the parents' DNA.

17 Feb 2015

Study shows amyloid formation may link type 2 diabetes and Alzheimer disease

The pathological process amyloidosis, in which misfolded proteins (amyloids) form insoluble fibril deposits, occurs in many diseases, including Alzheimer disease (AD) and type 2 diabetes mellitus (T2D).

17 Feb 2015

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira, Inc., a world leader in the development of biosimilar therapies, today announced the launch of the first biosimilar monoclonal antibody (mAb), Inflectra (infliximab), in major European markets.

16 Feb 2015

Research finding could lead to new therapeutic target for treating hypertension in males

Higher levels of a "danger" molecule may be one reason males tend to become hypertensive earlier and more severely than females, scientists say.

16 Feb 2015

New antibody shows promise in increasing survival for patients suffering from influenza, pneumonia

Scientists from NTU Singapore, the world's No. 1 young university, have developed an antibody which boosts the survival chances for patients suffering from influenza and pneumonia.

14 Feb 2015

$Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC$

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).

13 Feb 2015

Retinal venular calibre predicts ranibizumab vision improvement

Retinal venular calibre may predict visual outcome in diabetic macular oedema patients given the anti-vascular endothelial growth factor monoclonal antibody ranibizumab, a pilot study suggests.

13 Feb 2015

Elusys presents positive results of obiltoxaximab for treating inhalational anthrax, post-exposure prophylaxis

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented data demonstrating that obiltoxaximab (ETI-204) demonstrated a statistically significant survival benefit across a range of disease severity in animal model studies assessing treatment of inhalational anthrax, as well as effectiveness in post-exposure prophylaxis.

13 Feb 2015

InterveXion receives federal grants for development of drug therapies to treat methamphetamine users

A University of Arkansas for Medical Sciences BioVentures startup company, InterveXion Therapeutics LLC, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break their addiction.

12 Feb 2015

NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

NanoSmart Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, has received Orphan Drug Designation from the Food and Drug Administration for one of its lead candidates, antinuclear antibody (ANA) conjugated liposomal doxorubicin.

11 Feb 2015

Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline safety and tolerability results from a Phase 1b clinical trial of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.

10 Feb 2015

Researchers develop quality assurance tool for genome editing

A research team at Boston Children's Hospital's Program in Cellular and Molecular Medicine has developed a quality assurance tool for scientists using genome-editing technologies like the increasingly popular CRISPR. The assay, called high throughput genome translocation sequencing (HTGTS), rapidly gauges—for any given gene—these technologies' accuracy and their risk for causing potentially dangerous genomic collateral damage.

9 Feb 2015

Preclinical testing of anti-Ebola antibodies can lead to universal flu vaccine

Does the blood of Ebola virus disease survivors contain antibodies and immune cells that could help doctors fight Ebola infections in other people?

9 Feb 2015

New AGA guideline provides guidance to prevent HBV reactivation

Long-term immunosuppressive therapy can cause the hepatitis B virus (HBV) to become active, even in patients who are not aware that they are infected with the virus. A new guideline from the American Gastroenterological Association provides guidance to physicians and patients who use immunosuppressive agents for the treatment of a variety of disorders, including gastrointestinal, dermatologic, neurologic and rheumatologic, among others.

9 Feb 2015

Scientists develop potential new therapy based on cow's immune molecules for hormone deficiencies

To help people with hormone deficiencies, scientists at The Scripps Research Institute have developed a potential new therapy based on an unlikely model: immune molecules from cows.

9 Feb 2015

Helsinn begins elsiglutide Phase IIB trial for prevention of chemotherapy-induced diarrhea

Helsinn Healthcare S.A. and Zealand Pharma A/S jointly announce that Helsinn has started a Phase IIB clinical dose-finding trial of elsiglutide for the prevention of chemotherapy-induced diarrhea (CID). The first patients out of a planned total of 600 patients with colorectal cancer treated with chemotherapy have been dosed in the trial.

8 Feb 2015

Chemotherapy or immunosuppressive treatment may reactivate HBV

Individuals previously infected with the hepatitis B virus (HBV) who receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the disease according to a summary of report from the Emerging Trends Conference, "Reactivation of Hepatitis B," and published in Hepatology, a journal of the American Association for the Study of Liver Diseases.

6 Feb 2015

Antibody News and Research

Further Reading

New molecule shows promise in controlling HIV without using daily antiretroviral drugs

UCSD researchers make new attempt to develop malaria vaccine candidate

San Francisco AIDS Foundation unveils new mobile testing unit

Bacteria's DNA can pass trait to offspring in a way similar to parents' own DNA

Study shows amyloid formation may link type 2 diabetes and Alzheimer disease

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Research finding could lead to new therapeutic target for treating hypertension in males

New antibody shows promise in increasing survival for patients suffering from influenza, pneumonia

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Retinal venular calibre predicts ranibizumab vision improvement

Elusys presents positive results of obiltoxaximab for treating inhalational anthrax, post-exposure prophylaxis

InterveXion receives federal grants for development of drug therapies to treat methamphetamine users

NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Researchers develop quality assurance tool for genome editing

Preclinical testing of anti-Ebola antibodies can lead to universal flu vaccine

New AGA guideline provides guidance to prevent HBV reactivation

Scientists develop potential new therapy based on cow's immune molecules for hormone deficiencies

Helsinn begins elsiglutide Phase IIB trial for prevention of chemotherapy-induced diarrhea

Chemotherapy or immunosuppressive treatment may reactivate HBV

Monoclonal Antibody Manufacturing Trends eBook eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News